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Abstract
Aim—In the literature, there is evidence suggesting an association between substance use and 
psychosis. However, little is known about substance use in those who may be in the pre-psychotic 
phase, that is, those who are putatively prodromal are considered to be at clinical high risk (CHR) 
of developing psychosis.
Methods—We conducted a review of publications measuring patterns and rates of substance use 
in CHR for psychosis individuals and the effects on the transition to psychosis.
Results—Of 5527 potentially relevant research papers, 10 met inclusion criteria of CHR subjects 
and specifically mentioned substance use in the sample. The results of these studies varied. 
Cannabis, alcohol and tobacco/nicotine were reported as the most commonly used substances. 
There was limited information on the changes in patterns of use over time. Two out of the ten 
studies found a significant association between the use of substances and subsequent transition to 
psychosis. In one of these studies, substance abuse was a predictor of psychosis when included as 
a variable in a prediction algorithm. In the other study, the abuse of cannabis and nicotine was 
associated with transition to psychosis.
Conclusions—We found limited evidence to suggest that increased rates of substance use may 
be associated with transition to psychosis. However, further prospective research examining the 
association between substance use and transition to psychosis is required before any firm 
conclusions can be made.
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INTRODUCTION
High rates of substance use are commonly reported in patients with schizophrenia, with data 
from the United States suggesting that patients are 4.6 times more likely to use and abuse 
substances than the general population.1 In these studies, substance use typically refers to 
the use of alcohol, cannabis and other street drugs with some studies, including nicotine. 
Similar rates are reported for those individuals experiencing their first episode of 
psychosis,2-4 ranging from 22% to over 50%.5-10 These variations in rates may be accounted 
for by methodological differences such as sample selection, the use of different diagnostic 
criteria, and cultural and environmental differences between countries, such as the 
availability of substances.11,12 Furthermore, it has been demonstrated that substance use and 
abuse in first-episode psychosis is associated with increased hospitalizations,13,14 reduced 
treatment compliance,15-17 higher relapse rates18 and increased costs for mental health 
service providers.19
Epidemiological studies have found associations between substance use, generally cannabis, 
although a recent innovative study examines methamphetamine use,20 and increased risk of 
developing psychotic symptoms.21,22 However, there has been some controversy concerning 
the causal nature of this relationship.23 The current interest in prospective research that 
examines individuals who are at clinical high risk (CHR) of developing psychosis offers a 
unique opportunity to clarify the relationship by examining substance use prior to the onset 
of psychosis in a cohort with a greater likelihood of developing psychosis compared with the 
general population. A recent meta-analysis of CHR studies found that the rates of transition 
to psychosis increase over time, with an 18% chance after six months, 22% after one year, 
29% after two years and 36% after three years.24 The effect of substance use during this 
vulnerable stage is still unclear; however, given the evidence to suggest its deleterious effect 
in early psychosis, it is important to identify any possible role it may play in the earliest 
stages of the illness.
The purpose of the current review is to increase our understanding of the prevalence of 
substance use in CHR populations and its putative relationship with transition to psychosis. 
Our aims were, therefore, to review all CHR studies to date that have reported directly on 
substance use to determine: (i) the patterns and rates of substance use in CHR individuals 
and (ii) the potential role of substance use in the transition to psychosis.
METHODS
Search method
Relevant papers on substance use in CHR individuals were identified using the following 
search engines ‘CINAHL’, ‘EMBASE’, ‘MEDLINE’, ‘PsycINFO’, ‘PubMed’ and ‘Web of 
Science’ in July 2013. To identify relevant papers, the keywords and subject headings used 
included ‘clinical high risk’, ‘attenuated positive symptoms’, ‘brief intermittent psychotic 
symptoms’, ‘genetic risk and deterioration’, ‘basic symptoms’, ‘familial high risk’, 
‘substance use’, ‘substance abuse’, ‘substance use disorder’, ‘cannabis’, ‘marijuana’, 
‘tobacco’, ‘alcohol’, ‘amphetamine’, ‘hallucinogens’, ‘risk factors’, ‘psychosis’ and 
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‘schizophrenia’. The truncated keyword ‘prodrom*’ was also used as to include both 
‘prodrome’ and ‘prodromal’.
The search included papers published between 1995 and 3 July 2013. Our overall search, 
after removing duplicates, resulted in 5527 potentially relevant papers. The first step was to 
read the title and abstract to validate inclusion and, if necessary, the entire article to identify 
studies that mentioned substance use among CHR populations. This selection was carried 
out by NC with consultation with JA.
Inclusion and exclusion criteria
Papers were sifted for relevance to the review. Papers were included if they: (i) had been 
published in English-language peer-reviewed journals; (ii) contained information on 
prevalence of substance use in CHR populations; and (iii) reported effects of substance use 
on conversion rates to psychosis in CHR populations. Papers were excluded where CHR 
criteria were not clearly met and in which there was no reference to substance use. CHR 
criteria were met by studies that used internationally recognized diagnostic instruments, 
including the Structured Interview for Prodromal Syndromes/Scale of Prodromal Symptoms 
(SIPS/SOPS),25 Comprehensive Assessment of the At-Risk Mental State (CAARMS),26 
Schizophrenia Proneness Instrument, Adult Version (SPI-A),27 Schizophrenia Proneness 
Instrument, Child and Youth Version (SPI-CY)28 and Basel Screening Instrument for 
Psychosis (BSIP).29
Although the specific CHR criteria derived from these instruments vary, most studies 
consider subjects to be at CHR for psychosis if they fall into one of the following categories: 
(i) ‘attenuated positive symptoms’ (APS), defines individuals who have symptoms that 
deviate from ‘normal’ phenomena but which are not frankly psychotic, for example, hearing 
voices or having increased levels of suspiciousness; (ii) ‘brief intermittent psychotic 
symptoms’, defines individuals who have symptoms of ‘psychotic intensity’ but which is 
intermittent and spontaneously remitting; (iii) ‘genetic risk and deterioration’, defines 
individuals who have ‘non-specific’ symptoms such as lowered mood or anxiety symptoms 
plus some trait risk factor for psychotic disorder, such as family history of psychosis in first-
degree relative or schizotypal personality disorder; or (iv) ‘Basic Symptoms’, defined by 
subtle disturbances of cognition and perception.
RESULTS
The search strategy resulted in identifying 10 articles that reported substance use in 
individuals at CHR for the development of psychosis (see Table 1). We also found a recent 
review40 examining the impact of cannabis use on prodromal symptoms and transition to 
psychosis. This review identified 11 studies, 6 of which are also included in our review. The 
remainder were not included as four did not address conversion to psychosis and the fifth41 
focused on levels of anandamide in a small subsample.
Clinical diagnoses of CHR and substance abuse
In the studies currently under review, two different diagnostic instruments have been used to 
assess CHR criteria. Eight of the studies used the SIPS/SOPS,31-38 and two used the 
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CAARMS.30,39 Substance use/abuse was assessed by a range of instruments, including the 
Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 
Fourth Edition (DSM-IV) Disorders (SCID),42 the Composite International Diagnostic 
Interview (CIDI),43 Schedules for Clinical Assessment in Neuropsychiatry (SCAN),44 
Diagnostic Interview for Genetic Studies (DIGS)45 and the two versions of the Kiddie 
Schedule for Affective Disorders and Schizophrenia: the Present and Lifetime Version (K-
SADS-PL)46 and the Epidemiological Version (K-SADS-E).47 Substance use disorders were 
defined according to DSM-IV criteria in all of the studies. Five studies32,34,37,38,48 excluded 
participants with substance-induced APS (three of which37,38,48 also excluded participants 
who use hard drugs). The remaining two studies31,36 listed current substance dependence as 
an exclusion criterion for their samples. Two studies30,39 excluded participants who have 
used antipsychotic medications. One of the studies33 did not mention any exclusion criteria 
in relation to substance use.
Prevalence of cannabis use
Unfortunately, not all of the studies offered details on the types of substances used and the 
rates at which they were used. The most commonly used substance reported was cannabis, 
with rates varying in the studies from 33% to 54%.30-32,35-38 These fall in the mid-range of 
those reported in first-episode psychosis studies (e.g. 13–64%).4,10,49 Only two studies 
included a healthy control group, one of which demonstrated that CHR participants were 
significantly more likely to use cannabis than healthy controls,36 whereas the other study 
was unable to compare the two groups due to methodological differences.38
Five of the studies reported frequency of cannabis use,30,35-38 with two studies reporting no 
specific data.31,32 Auther et al.36 found that 49% of lifetime cannabis users had used 
cannabis 1–19 times and 51% of users had used cannabis 20 or more times. In one of their 
studies, Dragt et al.48 reported that 42% of total participants had used cannabis more than 
five times in their lifetime, and in the other,37 60% of recent cannabis users used almost 
daily, 13% used three to four times per week, 20% used one to two times per week, and 7% 
used one to three times per month. These results paralleled those of Korver et al.38 who 
claimed that 63% of recent cannabis users used almost daily, 13% used three to four times 
per week, 19% used one to two times per week, and 6% used one to three times per month. 
Finally, according to Phillips et al.30 in the year prior to recruitment, 19% of total 
participants had used cannabis at least one time but less than one time per week, and 37% of 
participants had used cannabis at least once a week.
In relation to DSM-IV diagnoses, the highest prevalence (33%) of cannabis use disorders 
(abuse or dependence in remission) was reported by Kristensen and Cadenhead.31 The other 
studies reported a lower incidence of cannabis use disorders ranging between 10% and 
32%.30,32,35-37
In summary, although there is some variation in the rates of cannabis use, generally about 
half the samples are using or have used, with reported prevalence rates being similar to those 
reported for those experiencing a first episode of psychosis. Rates were higher than healthy 
controls but that was only reported in one study.36
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Prevalence of alcohol use
Alcohol was the next most frequently used substance reported. Data on the use of alcohol 
were included in four of the studies,31,32,34,36 with rates ranging between 17% and 44%. 
With the exception of Auther et al.,36 none of these studies reported frequencies nor 
amounts.
Auther et al.36 reported alcohol as being the most frequently used substance with 44% of 
their sample. They reported lifetime use of alcohol with frequencies ranging between 1–2 
times ever (43.9%) and 5–7 days per week (2.4%) and quantities ranging from 1–2 drinks 
(48.4%) to six or more drinks (12.9%). Similar rates and patterns were found in the healthy 
comparison subjects in this study. In the other three studies, the use of alcohol ranged 
between 17% and 40%.31,32,34
In relation to DSM-IV alcohol disorder diagnoses, data were provided by three of the 
studies.31,32,34 Kristensen and Cadenhead31 reported that 10% of their sample had a 
diagnosis of abuse and 6% of dependence in remission, with Corcoran et al.32 also reporting 
a 6% dependence in remission and Ruhrmann et al.34 reporting 30% of their sample was 
diagnosed with alcohol abuse.
In summary, alcohol is used frequently by CHR participants. However, only one study 
reports comparable use to same-aged healthy peers.36
Prevalence of other substance use
The information presented on substances other than cannabis and alcohol which were used/
abused by the CHR samples was limited. Furthermore, where the rates of these substances 
were reported, they were minimal. The most commonly used substance other than cannabis 
and alcohol was tobacco/nicotine.31,32,36 The highest rate of lifetime use was reported by 
Author et al.,36 who reported that 34% of their sample had a lifetime history of smoking 
tobacco. The other two studies had a range of lifetime use from 16% to 17%.31,36
The use of other illicit substances was also considerably lower compared with cannabis. 
These substances included opioids, sedatives (i.e. barbiturates), stimulants (i.e. cocaine, 
amphetamines, ecstasy), hallucinogens (i.e. PCP) and solvents. From these substances, the 
use of hallucinogens was reported as the highest, ranging from 7% to 19%.30,32,36 The 
remaining substances had a range of use of 0–9%. The only study that reported data on 
DSM-IV diagnoses for any of these other substances was Kristensen and Cadenhead.31 They 
reported that 4% of their participants met criteria for either lifetime amphetamine abuse or 
dependence in remission.
These results suggest that use of substances other than cannabis, alcohol and tobacco/
nicotine is minimal in CHR populations, reflecting those findings in first-episode psychosis 
studies.
Changes over time in substance use
Although all of the studies were longitudinal with follow-up periods ranging between 12 and 
36 months, none reported on changes over time in substance use. The only exception was 
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Corcoran et al.,32 who reported no incident drug use in their ‘non-user’ group at follow-up 
and little or no change in amounts used in the ‘user’ group. Kristensen and Cadenhead31 and 
Dragt et al.48 took changes over time in substance use into account by assessing drug use at 
each follow-up assessment in addition to baseline.
Substance use and conversion to psychosis
All of the studies included in the review addressed the issue of conversion to psychosis, with 
only two reporting a significant association between substance use and transition to 
psychosis.31,33 Kristensen and Cadenhead31 found that CHR individuals were more likely to 
develop psychosis within one year if they had used cannabis and nicotine. In this study, 6 
(12.5%) of the 48 CHR individuals made the transition to psychosis, with 5 of these 
individuals meeting criteria for current cannabis abuse or cannabis dependence in remission, 
thus showing a significant association between cannabis use and conversion to psychosis. 
However, because this study was also examining psychophysiological and 
neuropsychological variables, individuals with current cannabis dependence had been 
excluded from the study to avoid the risk of affecting the psychophysiological and 
neuropsychological test measures. Nicotine was also reported to be significantly associated 
with later conversion to psychosis with four out of the five cannabis using participants also 
using nicotine.
The only other study to find an association between substance use and transition to 
psychosis was the Cannon et al.33 study, which had the largest sample (n = 291) and a 
transition rate of 35% during a 2.5-year follow-up. They found that a history of any 
substance use disorder was one of five predictors of conversion to psychosis when it was 
included in their prediction model.
Auther et al.36 did not find any association between age of cannabis onset and age of 
psychosis onset. However, two studies37,48 found that a younger age of onset of cannabis 
use resulted in a younger age of psychosis symptom onset. Thus, the majority of studies to 
date are not reporting a role for substance use in later conversion to psychosis.
DISCUSSION
The study of young people at risk of developing psychosis is a relatively new area and the 
literature is limited in addressing the issue of substance use in these populations. To the best 
of our knowledge, there are only 10 studies addressing this issue. Cannabis, alcohol and 
nicotine were found to be the most commonly used substances in CHR populations, with the 
use of cannabis and nicotine being higher than in healthy controls,36 and with rates being 
similar to those at the first episode of psychosis.2-4,50 The use of other substances was either 
minimal or absent. With the exception of two studies,31,33 there was little evidence to 
suggest an association between substance use/abuse and transition to psychosis in a CHR 
population.
A possible explanation as to why the rates of cannabis use in CHR populations are similar to 
those found in first-episode psychosis cohorts is that CHR individuals may use cannabis to 
help alleviate some of their symptoms, for instance, anxiety, depression or negative 
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symptoms. This explanation is in line with the ‘self-medication’ hypothesis of cannabis use 
in psychosis which predicts that individuals may be using cannabis due in large part to their 
predisposition to psychosis. Some support for this theory is found in the Dragt et al.35 study. 
Another possibility is that individuals who are prone to psychosis have a neurobiological 
predisposition to both cannabis use and psychotic illness. Patients with schizophrenia and 
CHR individuals have been shown to have abnormalities of the endocannabinoid system. 
For example, anandamide, an endogenous CB1 receptor agonist, is elevated in the 
cerebrospinal fluid of antipsychotic- and cannabis-naïve patients with schizophrenia51 and in 
CHR subjects.41 In addition, translational studies have demonstrated the role of the 
endocannabinoid system in dopamine regulation.52,53
Only in two of the reviewed studies was cannabis use significantly associated with transition 
to psychosis.31,33 A possible explanation for this lack of association could be that the use of 
cannabis may be considered a predictor for the development of CHR symptoms, but 
cannabis use during the CHR phase may not differentiate between those who develop 
psychosis and those who do not. For transition to occur, other environmental54 and genetic 
factors55 may be necessary to contribute to the pathway that leads to psychosis.
In one of the two studies that found a significant association between substance use and 
transition to psychosis,40 no specific substance class of the seven substances tested (i.e. 
alcohol, cannabis, hypnotics, amphetamines, opiates, cocaine and hallucinogens) were 
significantly associated with conversion but only having a history of a DSM-IV diagnosis of 
a substance use disorder. In this study, the low base rate of substance abuse severely limited 
sensitivity. In the Kristensen and Cadenhead31 study, the substance using group was 
categorized as those who met criteria for cannabis use disorders, thus, ensuring that the 
using group was well-defined diagnostically, although conversion rates were low. Ruhrmann 
et al.34 was the only other study under review to define cannabis using in this way, with all 
of the other studies dividing their groups according to cannabis use versus no use. If the 
dose-dependent hypothesis was to be considered, then it may not be surprising that an 
association between cannabis use and transition to psychosis was not found, although 
several of the other studies32,37,38,48 also looked at cannabis abuse but did not find a 
significant relationship with psychosis.
There are several limitations with the current studies. Firstly, the longitudinal use/abuse of 
substances has not been adequately addressed in the current studies. The only study that 
attempted to do this was the Corcoran et al.32 study that looked at the temporal patterns of 
cannabis use and prodromal symptoms and found an association with one positive symptom. 
Other studies focused on lifetime or baseline levels of use rather than continued use over the 
follow-up period, which could have affected the outcome.22,56 Furthermore, it has been 
demonstrated that a substantial proportion of subjects show improvements in symptoms over 
time,57 and this improvement might extend to other areas as well such as reduced symptoms 
of depression, anxiety and substance use, especially if treatment is being provided. It is, 
therefore, necessary to look more closely at patterns of substance use over the follow-up 
period.
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Secondly, the majority of studies lacked details on severity, frequency and quantity of 
substance use. Specifically in relation to cannabis, no details were provided on the types of 
cannabis used as research has shown that varying potencies of cannabis can have significant 
effects on symptom severity with high concentrations of 9-tetrahydrocannabinol, leading to 
more severe positive symptoms.58 In addition, some of the current data come from research 
projects where there was an exclusion criterion with respect to substance dependence. This 
limited these samples to those with less severe substance use, which could affect outcomes if 
the relationship between substance use and conversion is dose dependent.59-62 For example, 
a recent study20 examining individuals with methamphetamine-related conditions found that 
this group had a higher risk of developing schizophrenia than other medical conditions and 
other substances, with the exception of cannabis use disorders where the risk was the same. 
It is possible that studies may exclude methamphetamine users or that such users may not be 
those who present themselves for inclusion in a research project.
Thirdly, the prevalence of substance use in these CHR populations relative to the general 
population is unclear. Only one study had a healthy comparison group. Fourthly, although 
the CHR group represents a population that is at increased risk for the development of 
psychosis compared with the general population, many CHR individuals will not go on to 
develop psychosis33 and the rates of conversion seem to be declining.63 Therefore, studies 
examining the relationship between substance use and transition to psychosis may not be 
finding any significant associations partly due to insufficient power in relation to small 
sample sizes and a low base rate of substance use. Furthermore, the recency and amounts of 
substances used considerably differs between the current studies, making it difficult to make 
accurate comparisons.
Finally, an important methodological issue that needs to be addressed when attempting to 
explore a causal relationship between factors, in this case substance use and psychosis, is 
controlling for potentially confounding factors. In studies examining conversion, this was 
not specifically addressed. Some of the potential control factors would include method of 
ascertainment of subjects, inclusion and exclusion criteria particularly, age of participants 
which typically vary from 12 to 31, age at first use of substances particularly cannabis, 
assessment of substance use which should include type and quantities and possibly 
biological measures, co-morbid diagnoses (e.g. mood disorders), medications including 
antipsychotics and other potential risk factors such as family history.
In conclusion, the literature examining substance use in those at CHR is limited. The 
majority of studies have not found a relationship between substances, mainly cannabis use 
and psychosis. Certainly, studies with a more comprehensive and longitudinal approach to 
assessing substance use are required. Although the low base rates currently being reported of 
substance use clearly limits sensitivity, its association with risk of transition is theoretically 
important as it is possible that a substance-related mechanism may be capable of promoting 
brain changes in certain high-risk individuals and it may only be in the context of other 
factors, such as family history, environmental risk factors or genetic background that a 
relationship is found.
Addington et al. Page 8
Early Interv Psychiatry. Author manuscript; available in PMC 2015 March 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
REFERENCES
1. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug 
abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990; 264:2511–8. 
[PubMed: 2232018] 
2. Sevy S, Robinson DG, Solloway S, et al. Correlates of substance misuse in patients with first-
episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand. 2001; 104:367–74. 
[PubMed: 11722318] 
3. Wade D, Harrigan S, Whelan G, Burgess P, McGorry P. The impact of substance use disorders on 
clinical outcome in first episode psychosis. Schizophr Res. 2004; 67(Suppl. 1):B172.
4. Barnett JH, Werners U, Secher SM, et al. Substance use in a population-based clinic sample of 
people with first-episode psychosis. Br J Psychiatry. 2007; 190:515–20. [PubMed: 17541112] 
5. Strakowski SM, Tohen M, Stoll AL, et al. Comorbidity in psychosis at first hospitalization. Am J 
Psychiatry. 1993; 150:752–7. [PubMed: 8480821] 
6. Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry. 1996; 
40:1–9. [PubMed: 8780848] 
7. Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L, Miller A, Bromet E. Substance use 
disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull. 
1997; 23:195–201. [PubMed: 9165630] 
8. Rabinowitz J, Bromet EJ, Lavelle J, Carlson G, Kovasznay B, Schwartz JE. Prevalence and severity 
of substance use disorder and onset of psychosis in first-admission psychotic patients. Psychol Med. 
1998; 28:1411–9. [PubMed: 9854282] 
9. Cantwell R, Brewin J, Glazebrook C, et al. Prevalence of substance misuse in first-episode 
psychosis. Br J Psychiatry. 1999; 174:150–3. [PubMed: 10211169] 
10. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis 
program. Soc Psychiatry Psychiatr Epidemiol. 2004; 39:69–72. [PubMed: 15022049] 
11. Kamali M, McTigue O, Whitty P, et al. Lifetime history of substance misuse in first episode 
psychosis: prevalence and its influence on psychopathology and onset of psychotic symptoms. 
Early Interv Psychiatry. 2009; 3:198–203. [PubMed: 22640383] 
12. Mazzoncini R, Donoghue K, Hart J, et al. Illicit substance use and its correlates in first episode 
psychosis. Acta Psychiatr Scand. 2010; 121:351–8. [PubMed: 19824986] 
13. Bartels S, Teague G, Drake R, Clark R, Bush PW, Noordsy DL. Substance abuse in schizophrenia: 
service utilization and costs. J Nerv Ment Dis. 1993; 181:227–32. [PubMed: 8473874] 
14. Haywood T, Kravitz H, Grossman L, Cavanaugh J, Davis J, Lewis D. Predicting the ‘revolving 
door’ phenomenon amoung patients with schizophrenic schizoaffective, and affective disorders. 
Am J Psychiatry. 1995; 152:856–60. [PubMed: 7755114] 
15. Owen R, Fischer E, Booth B, Cuffel B. Medication noncompliance and substance abuse among 
patients with schizophrenia. Psychiatr Serv. 1996; 46:853–8. [PubMed: 8837158] 
16. Lambert M, Conus P, Lubman DI, et al. The impact of substance use disorders on clinical outcome 
in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005; 112:141–8. [PubMed: 
15992396] 
17. Miller BJ. A review of secong generation antipsychotic discontinuation in first episode psychosis. J 
Psychiatr Pract. 2008; 14:289–300. [PubMed: 18832960] 
18. Malla A, Norman R, Bechard-Evans L, Schmitz N, Manchanda R, Cassidy C. Factors influencing 
relapse during a 2 year follow up of first episode psychosis in a specialized early intervention 
service. Psychol Med. 2008; 38:1585–93. [PubMed: 18205969] 
19. Lambert M, Naber D, Schacht A, et al. Rates and predictors of remission and recovery during 3 
years in 392 never treated patients with schizophrenia. Acta Psychiatr Scand. 2008; 118:220–9. 
[PubMed: 18699954] 
20. Callaghan RC, Cunningham JK, Allebeck P, et al. Methamphetamine use and schizophrenia: a 
population-based cohort study in California. Am J Psychiatry. 2012; 169:389–96. [PubMed: 
22193527] 
Addington et al. Page 9
Early Interv Psychiatry. Author manuscript; available in PMC 2015 March 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
21. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective 
mental health outcomes: a systematic review. Lancet. 2007; 370(9584):319–28. [PubMed: 
17662880] 
22. Kuepper R, van Os J, Lieb R, Wittchen HU, Hofler M, Henquet C. Continued cannabis use and 
risk of incidence and persistence of psychotic symptoms: 10 year follow up cohort study. BMJ. 
2011; 342:d738. [PubMed: 21363868] 
23. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and 
psychosis: examination of the evidence. Br J Psychiatry. 2004; 184:110–17. [PubMed: 14754822] 
24. Fusar-Poli P, Bonoldi L, Yung A, et al. Predicting psychosis: meta-analysis of transition outcomes 
in idividuals at high clinical risk. Arch Gen Psychiatry. 2012; 69:220–9. [PubMed: 22393215] 
25. McGlashan, T.; Walsh, BC.; Woods, SW. The Psychosis Risk Syndrome: Handbook for Diagnosis 
and Follow-up. Oxford University Press; New York: 2010. 
26. Yung AR, Yuen HP, McGorry PD, et al. Mapping the onset of psychosis: the Comprehensive 
Assessment of At-Risk Mental States. Aust N Z J Psychiatry. 2005; 39(11-12):964–71. [PubMed: 
16343296] 
27. Schultze-Lutter, F.; Addington, J.; Ruhrmann, S.; Klosterkotter, J. Schizophrenia Proneness 
Instrument, Adult Version (SPI-A). Giovanni Fiorito Editore; Rome: 2007. 
28. Schultze-Lutter, F.; Marshall, M.; Koch, E. Schizophrenia Proneness Instrument: Child and Youth 
Version (SPI-CY). Giovanni Fiorito Editore; Rome: 2012. Extended English Translation
29. Reicher-Rossler A, Aston J, Ventura J, et al. The Basel Screening Instrument for Psychosis (BSIP): 
development, structure, reliability and validity (in German). Fortschr Neurol Psychiatr. 2008; 
76:207–16. [PubMed: 18393134] 
30. Phillips LJ, Curry C, Yung AR, Yuen H, Adlard S, McGorry PD. Cannabis use is not associated 
with the development of psychosis in an ‘ultra’ high-risk group. Aust N Z J Psychiatry. 2002; 
36:800–6. [PubMed: 12406123] 
31. Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. 
Psychiatry Res. 2007; 151(1-2):151–4. [PubMed: 17383738] 
32. Corcoran CM, Kimhy D, Stanford A, et al. Temporal association of cannabis use with symptoms in 
individuals at clinical high risk for psychosis. Schizophr Res. 2008; 106(2-3):286–93. [PubMed: 
18809298] 
33. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: 
a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008; 65:28–37. [PubMed: 
18180426] 
34. Ruhrmann S, Schultze-Lutter F, Salokangas RK, et al. Prediction of psychosis in adolescents and 
young adults at high risk: results from the prospective European prediction of psychosis study. 
Arch Gen Psychiatry. 2010; 67:241–51. [PubMed: 20194824] 
35. Dragt S, Nieman DH, Schultze-Lutter F, et al. Cannabis use and age at onset of symptoms in 
subjects at clinical high risk for psychosis. Acta Psychiatr Scand. 2012; 125:45–53. [PubMed: 
21883099] 
36. Auther AM, McLaughlin D, Carrion RE, Nagachandran P, Correll CU, Cornblatt BA. Prospective 
study of cannabis use in adolescents at clinical high risk for psychosis: impact on conversion to 
psychosis and functional outcome. Psychol Med. 2012; 42:2485–97. [PubMed: 22716931] 
37. Dragt S, Nieman DH, Becker HE, et al. Age of onset of cannabis use is associated with age of 
onset of high-risk symptoms for psychosis. Can J Psychiatry. 2010; 55:165–71. [PubMed: 
20370967] 
38. Korver N, Nieman DH, Becker HE, et al. Symptomatology and neuropsychological functioning in 
cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. Aust N Z 
J Psychiatry. 2010; 44:230–6. [PubMed: 20180725] 
39. Thompson A, Nelson B, Yung A. Predictive validity of clinical variables in the ‘at risk’ for 
psychosis population: international comparison with results from the North American Prodrome 
Longitudinal Study. Schizophr Res. 2011; 126(1-3):51–7. [PubMed: 21035313] 
40. van der Meer FJ, Velthorst E, Meijer CJ, Machielsen MW, de Haan L. Cannabis use in patients at 
clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Curr 
Pharm Des. 2012; 18:5036–44. [PubMed: 22716158] 
Addington et al. Page 10
Early Interv Psychiatry. Author manuscript; available in PMC 2015 March 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
41. Koethe D, Giuffrida A, Schreiber D, et al. Anandamine elevation in cerebrospinal fluid in initial 
prodromal states of psychosis. Br J Psychiatry. 2009; 194:371–2. [PubMed: 19336792] 
42. First, M.; Spitzer, RL.; Gibbon, M.; Williams, B.; Williams, JBW. Structured Clinical Interview 
for DSM-IV Axis I Disorders, Patient Edition. Biometrics Research Department, New York State 
Psychiatric Institute; New York: 1995. 
43. Andrews G, Peters L. The psychometeric properties of the Composite International Diagnostic 
Interview. Soc Psychiatry Psychiatr Epidemiol. 1998; 33:80–8. [PubMed: 9503991] 
44. Wing J, Babor T, Brugha T, Burke J. SCAN: schedules for clinical assessment in neuropsychiatry. 
Arch Gen Psychiatry. 1990; 47:589–93. [PubMed: 2190539] 
45. Nurnberger JI Jr, Blehar MC, Kaufmann CA, et al. Diagnostic interview for genetic studies. 
Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry. 1994; 
51:849–59. [PubMed: 7944874] 
46. Kaufman J, Birmaher B, Brent D, et al. Schedule for affective disorders and schizophrenia for 
school aged children present and lifetime version (K-SADS-PL): initial reliability and validity 
data. J Am Acad Child Adolesc Psychiatry. 1997; 36:980–8. [PubMed: 9204677] 
47. Orvaschel, HP-AJ. Schedule for affective disorders and schizophrenia for school – aged children -
epidemiologic version. Centre for Psychological Studies, Nova Southeastern University; Fort 
Lauderdale, FL: 1994. 
48. Dragt S, Nieman DH, Schultze-Lutter F, et al. Cannabis use and age at onset of symptoms in 
subjects at clinical high risk for psychosis. Acta Psychiatr Scand. 2012; 125(1):45–53. [PubMed: 
21883099] 
49. Barnes T, Mutsatsa S, Hutton SB, Watt H, Joyce E. Comorbid substance use and age at onset of 
schizophrenia. Br J Psychiatry. 2006; 188:237–42. [PubMed: 16507965] 
50. Cooper J, Mancuso S, Borland R, Slade T, Galletly C, Castle D. Tobacco smoking among people 
living with a psychotic illness: the second Australian survey of psychosis. Aust N Z J Psychiatry. 
2012; 46:851–63. [PubMed: 22645396] 
51. Leweke FM, Giuffrida A, Koethe D, et al. Anandamide levels in cerebrospinal fluid of first-
episode schizophrenic patients: impact of cannabis use. Schizophr Res. 2007; 94(1-3):29–36. 
[PubMed: 17566707] 
52. Galve-Roperh I, Palazuleous J, Aguado T, Guzman M. The endocannabinoid system and the 
regulation of neural development: potential implications in psychiatric disorders. Eur Arch 
Psychiatry Clin Neurosci. 2009; 259:371–82. [PubMed: 19588184] 
53. Koethe D, Hoyer C, Leweke FM. The endocannabinoid system as a target for modelling psychosis. 
Psychopharmacology (Berl). 2009; 206:551–61. [PubMed: 19529920] 
54. Fusar-Poli P, Borgwardt S, Bechdolf A, et al. The psychosis high risk sate: a comprehensive state 
of the art review. JAMA Psychiatry. 2013; 70:107–20. [PubMed: 23165428] 
55. Caspi A, Moffitt TE, Cannon M, et al. Moderation of the effect of adolescent-onset cannabis use 
on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: 
longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005; 57:1117–27. 
[PubMed: 15866551] 
56. Yucel M, Bora E, Lubman DI, et al. The impact of cannabis use on cognitive functioning in 
patients with schizophrenia: a meta-analysis of exisiting findings and new data in a first episode 
sample. Schizophr Bull. 2012; 38:316–30. [PubMed: 20660494] 
57. Addington J, Cornblatt B, Cadenhead K, et al. At clinical high risk for psychosis: outcome for non-
converters. Am J Psychiatry. 2011; 168(8):800–5. [PubMed: 21498462] 
58. Barkus E, Murray R. Substance use in adolescence and psychosis: clarifying the relationship. Annu 
Rev Clin Psychol. 2010; 6:365–89. [PubMed: 20192802] 
59. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. Lancet. 1988; 
1:1000–1. [PubMed: 2896812] 
60. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a 
longitudinal population-based study. Am J Epidemiol. 2002; 156:319–27. [PubMed: 12181101] 
61. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk 
factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002; 
325(7374):1199. [PubMed: 12446534] 
Addington et al. Page 11
Early Interv Psychiatry. Author manuscript; available in PMC 2015 March 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
62. Henquet C, Krabbendam L, Spauwen J, et al. Prospective cohort study of cannabis use, 
predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005; 330(7481):11. 
[PubMed: 15574485] 
63. Yung AR, Yuen HP, Berger G, et al. Declining transition rate in ultra high risk (prodromal) 
services: dilution or reduction of risk? Schizophr Bull. 2007; 33(3):673–81. [PubMed: 17404389] 
Addington et al. Page 12
Early Interv Psychiatry. Author manuscript; available in PMC 2015 March 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Addington et al. Page 13
TA
B
LE
 1
R
es
ea
rc
h 
stu
di
es
 d
em
on
str
at
in
g 
th
e 
pr
ev
al
en
ce
 o
f s
ub
sta
nc
e 
us
e 
in
 c
lin
ic
al
 h
ig
h 
ris
k 
po
pu
la
tio
ns
St
ud
y
Sa
m
pl
e
Fo
llo
w
-u
p
in
 m
on
th
s
N
um
be
r 
of
 p
ar
tic
ip
an
ts
 w
ho
ha
ve
 u
se
d 
su
bs
ta
nc
es
 a
t
ba
se
lin
e
N
um
be
r 
of
 
pa
rt
ic
ip
an
ts
 w
ho
m
et
 c
ri
te
ri
a 
fo
r 
at
 le
as
t 
o
n
e
su
bs
ta
nc
e 
us
e 
di
so
rd
er
Su
bs
ta
nc
e
u
se
 m
ea
su
re
N
um
be
r o
f c
on
ve
rs
io
ns
to
 p
sy
ch
os
is
C
on
cl
us
io
ns
Ph
ill
ip
s e
t a
l.3
0
49
 m
al
e, 
51
 fe
m
al
e, 
ag
ed
 
14
–3
0 
in
 M
el
bo
ur
ne
,
 
A
us
tra
lia
12
Ca
nn
ab
is 
= 
35
 (3
5.0
%)
O
pi
oi
ds
 =
 2
 (2
.0%
)
Se
da
tiv
es
 =
 2
 (2
.0%
)
Co
ca
in
e 
= 
0 
(0.
0%
)
St
im
ul
an
ts 
= 
7 
(7.
0%
)
H
al
lu
ci
no
ge
ns
 =
 7
 (7
.0%
)
So
lv
en
ts 
= 
1 
(1.
0%
)
Ca
nn
ab
is 
= 
18
 (1
8.0
%)
SC
A
N
12
 m
on
th
s:
Ca
nn
ab
is 
us
er
s =
 1
3 
(40
.6%
)
N
on
-c
an
na
bi
s u
se
rs
 =
 1
9
 
(59
.4%
)
A
 ro
le
 fo
r c
an
na
bi
s i
n 
th
e
 
de
ve
lo
pm
en
t o
f
 
ps
yc
ho
sis
 is
 n
ot
 
su
pp
or
te
d
K
ris
te
ns
en
 a
nd
Ca
de
nh
ea
d†
31
26
 m
al
e, 
22
 fe
m
al
e, 
ag
ed
 
12
–3
0,
 in
 S
an
 D
ie
go
,
 
U
SA
24
Ca
nn
ab
is 
= 
16
 (3
3.3
%)
A
lc
oh
ol
 =
 8
 (1
6.7
%)
A
m
ph
et
am
in
e 
= 
2 
(4.
2%
)
N
ic
ot
in
e 
= 
8 
(16
.7%
)
Ca
nn
ab
is 
= 
16
 (3
3.3
%)
A
lc
oh
ol
 =
 8
 (1
6.7
%)
A
m
ph
et
am
in
e 
= 
2 
(4.
2%
)
N
ic
ot
in
e 
= 
N
ot
 re
po
rte
d
SC
ID
K
-S
A
D
S-
PL
12
 m
on
th
s:
Ca
nn
ab
is 
us
er
s =
 1
N
on
-c
an
na
bi
s u
se
rs
 =
 1
Ca
nn
ab
is 
an
d 
ni
co
tin
e
 
u
se
rs
 =
 4
Si
gn
ifi
ca
nt
 a
ss
oc
ia
tio
n
 
be
tw
ee
n 
ca
nn
ab
is
 
ab
us
e 
an
d 
ni
co
tin
e 
us
e
 
an
d 
co
nv
er
sio
n 
to
 
ps
yc
ho
sis
Co
rc
or
an
et
 a
l.3
2
26
 m
al
e, 
6 
fe
m
al
e, 
ag
ed
 
12
–2
5,
 in
 N
ew
 Y
or
k,
 
U
SA
24
Ca
nn
ab
is 
= 
13
 (4
0.6
%)
A
lc
oh
ol
 =
 1
3 
(40
.6%
)
Co
ca
in
e 
= 
3 
(9.
4%
)
H
al
lu
ci
no
ge
ns
 =
 6
 (1
8.8
%)
St
im
ul
an
ts 
= 
1 
(3.
1%
)
To
ba
cc
o 
= 
5 
(16
%)
Ca
nn
ab
is 
= 
8 
(25
.0%
)
A
lc
oh
ol
 =
 2
 (6
.3%
)
Co
ca
in
e 
= 
1 
(3.
1%
)
K
-S
A
D
S-
PL
D
IG
S
N
o 
di
ffe
re
nc
es
 in
 c
on
ve
rs
io
n
 
ra
te
s 
be
tw
ee
n 
su
bs
ta
nc
e
 
u
se
rs
 a
n
d 
no
n-
us
er
s –
 
sp
ec
ifi
c 
nu
m
be
rs
 
u
n
av
ai
la
bl
e
Ca
nn
ab
is 
us
e 
m
ay
 b
e 
a
 
ris
k 
fa
ct
or
 fo
r t
he
 
ex
ac
er
ba
tio
n 
of
 
su
bt
hr
es
ho
ld
 p
sy
ch
ot
ic
 
sy
m
pt
om
s, 
sp
ec
ifi
ca
lly
 
pe
rc
ep
tu
al
 
di
stu
rb
an
ce
s, 
bu
t n
ot
 
fo
r c
on
ve
rs
io
n 
to
 
ps
yc
ho
sis
Ca
nn
on
 e
t a
l.3
3
17
0 
m
al
e,
 1
21
 fe
m
al
e,
 
ag
ed
 1
2–
35
, i
n 
N
or
th
 
A
m
er
ic
a
30
A
ny
 su
bs
ta
nc
e 
= 
27
0 
(92
.8%
)
Th
is 
in
cl
ud
ed
 u
se
 o
f a
ny
 o
f
 
th
e 
fo
llo
w
in
g 
dr
ug
s:
A
lc
oh
ol
H
yp
no
tic
s
Ca
nn
ab
is
A
m
ph
et
am
in
es
O
pi
at
es
Co
ca
in
e
H
al
lu
ci
no
ge
ns
N
ot
 re
po
rte
d
SC
ID
K
-S
A
D
S-
PL
82
 (3
5.3
%)
 co
nv
ers
ion
s,
 
n
o
 s
pe
ci
fic
 d
et
ai
ls 
on
 
di
ffe
re
nc
es
 b
et
w
ee
n
 
su
bs
ta
nc
e 
us
er
s a
nd
 
n
o
n
-u
se
rs
. 
Cu
m
ul
at
iv
e
 
co
n
v
er
sio
n 
ra
te
s o
ve
r
 
fo
llo
w
-u
p 
ar
e 
as
 fo
llo
w
s:
6 
m
on
th
s =
 1
2.
7%
12
 m
on
th
s =
 2
1.
7%
18
 m
on
th
s =
 2
6.
8%
28
 m
on
th
s =
 3
2.
6%
30
 m
on
th
s =
 3
5.
3%
H
ist
or
y 
of
 su
bs
ta
nc
e
 
ab
us
e 
pr
ed
ic
te
d
 
co
n
v
er
sio
n 
to
 p
sy
ch
os
is
 
al
th
ou
gh
 n
o 
sp
ec
ifi
c
 
su
bs
ta
nc
e 
w
as
 
sig
ni
fic
an
tly
 a
ss
oc
ia
te
d
 
w
ith
 ri
sk
R
uh
rm
an
n 
et
 a
l.3
4
13
7 
m
al
e,
 1
08
 fe
m
al
e,
 
ag
ed
 1
6–
35
, i
n 
Eu
ro
pe
18
A
ny
 d
ru
g 
= 
53
 (2
3.0
%)
A
lc
oh
ol
 =
 6
9 
(30
.0%
)
A
ny
 d
ru
g 
= 
53
 (2
3.0
%)
A
lc
oh
ol
 =
 6
9 
(30
.0%
)
CI
D
I
18
 m
on
th
s:
37
 c
on
ve
rs
io
ns
, n
o 
sp
ec
ifi
c
 
de
ta
ils
 o
n 
di
ffe
re
nc
es
 
be
tw
ee
n 
su
bs
ta
nc
e 
us
er
s
 
an
d 
no
n-
us
er
s
N
o 
as
so
ci
at
io
n 
be
tw
ee
n
 
su
bs
ta
nc
e 
ab
us
e 
an
d
 
co
n
v
er
sio
n 
to
 p
sy
ch
os
is
D
ra
gt
 e
t a
l.3
5
13
7 
m
al
e 
an
d 
10
8
 
fe
m
al
e,
 a
ge
d 
16
–3
5 
in
 
Eu
ro
pe
18
Ca
nn
ab
is 
= 
10
2 
(42
.0%
)
Ca
nn
ab
is 
= 
45
 (1
8.4
%)
CI
D
I
D
SM
-IV
18
 m
on
th
s:
Ca
nn
ab
is 
us
er
s =
 1
5
N
on
-c
an
na
bi
s u
se
rs
 =
 2
2
Ea
rly
 a
ge
 a
t o
ns
et
 o
f
 
ca
n
n
ab
is 
us
e 
is
 
as
so
ci
at
ed
 w
ith
 e
ar
lie
r
 
ap
pe
ar
an
ce
 o
f
Early Interv Psychiatry. Author manuscript; available in PMC 2015 March 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Addington et al. Page 14
St
ud
y
Sa
m
pl
e
Fo
llo
w
-u
p
in
 m
on
th
s
N
um
be
r 
of
 p
ar
tic
ip
an
ts
 w
ho
ha
ve
 u
se
d 
su
bs
ta
nc
es
 a
t
ba
se
lin
e
N
um
be
r 
of
 
pa
rt
ic
ip
an
ts
 w
ho
m
et
 c
ri
te
ri
a 
fo
r 
at
 le
as
t 
o
n
e
su
bs
ta
nc
e 
us
e 
di
so
rd
er
Su
bs
ta
nc
e
u
se
 m
ea
su
re
N
um
be
r 
of
 c
on
ve
rs
io
ns
to
 p
sy
ch
os
is
C
on
cl
us
io
ns
 
sy
m
pt
om
s, 
ho
w
ev
er
,
 
n
o
t r
el
at
ed
 to
 
co
n
v
er
sio
n 
to
 p
sy
ch
os
is
A
ut
he
r e
t a
l.3
6
66
 m
al
e, 
35
 fe
m
al
e, 
ag
ed
 
12
–2
2 
in
 N
ew
 Y
or
k,
 
U
SA
36
To
ba
cc
o 
= 
31
 (3
4.4
%)
Ca
nn
ab
is 
= 
35
 (3
6.5
%)
A
lc
oh
ol
 =
 4
3 
(44
.3%
)
A
m
ph
et
am
in
e 
= 
4 
(4.
2%
)
B
ar
bi
tu
ra
te
s =
 3
 (3
.1%
)
Co
ca
in
e 
= 
6 
(6.
2%
)
O
pi
oi
ds
 =
 8
 (8
.3%
)
PC
P 
= 
1 
(1.
0%
)
H
al
lu
ci
no
ge
n 
= 
11
 (1
1.5
%)
So
lv
en
ts 
= 
3 
(3.
1%
)
Ec
st
as
y 
= 
3 
(3.
1%
)
Ca
nn
ab
is 
= 
10
 (1
0.4
%)
K
-S
A
D
S-
E
N
o 
di
ffe
re
nc
es
 in
 c
on
ve
rs
io
n
 
ra
te
s 
be
tw
ee
n 
su
bs
ta
nc
e
 
u
se
rs
 a
n
d 
no
n-
us
er
s –
 
sp
ec
ifi
c 
nu
m
be
rs
 n
ot
 
av
ai
la
bl
e
Li
fe
tim
e 
ca
nn
ab
is
 
u
se
/a
bu
se
 d
o 
no
t
 
pr
ed
ic
t c
on
ve
rs
io
n 
to
 
ps
yc
ho
sis
D
ra
gt
 e
t a
l.‡
37
47
 m
al
e,
 2
1 
fe
m
al
e,
 a
ge
d
 
12
–3
5 
in
 A
m
ste
rd
am
,
H
ol
la
nd
N
ot
 re
po
rte
d
Ca
nn
ab
is 
= 
35
 (5
1.5
%)
Ca
nn
ab
is 
= 
22
 (3
2.4
%)
CI
D
I
U
p 
to
 3
7 
m
on
th
s: 
Ca
nn
ab
is
 
u
se
rs
 =
 5
 (2
9.4
%)
N
on
-c
an
na
bi
s u
se
rs
 =
 1
2
 
(70
.6%
)
Ea
rly
 a
ge
 a
t o
ns
et
 o
f
 
ca
n
n
ab
is 
us
e 
is
 
as
so
ci
at
ed
 w
ith
 e
ar
lie
r
 
ap
pe
ar
an
ce
 o
f
 
sy
m
pt
om
s, 
no
t r
el
at
ed
 
to
 c
on
ve
rs
io
n 
to
 
ps
yc
ho
sis
K
or
ve
r e
t a
l.3
8
42
 m
al
e,
 2
1 
fe
m
al
e,
 a
ge
d
 
12
–3
5 
in
 A
m
ste
rd
am
,
 
H
ol
la
nd
36
Ca
nn
ab
is 
= 
34
 (5
4.0
%)
N
ot
 re
po
rte
d
CI
D
I
Ca
nn
ab
is 
us
er
s =
 7
 (4
1.2
%)
N
on
-c
an
na
bi
s u
se
rs
 =
 1
0
 
(58
.8%
)
Ca
nn
ab
is 
us
e 
is 
re
la
te
d 
to
 
in
cr
ea
se
d 
sy
m
pt
om
s
 
an
d 
in
cr
ea
se
d 
sy
m
pt
om
 
se
v
er
ity
, n
ot
 re
la
te
d 
to
 
co
n
v
er
sio
n 
to
 p
sy
ch
os
is
Th
om
ps
on
 
et
 a
l.3
9
51
 m
al
e, 
53
 fe
m
al
e, 
ag
ed
 
14
–3
0 
in
 M
el
bo
ur
ne
,
 
A
us
tra
lia
28
A
ny
 su
bs
ta
nc
e 
= 
24
 (2
3.5
%)
N
ot
 re
po
rte
d
SC
ID
28
 m
on
th
s:
Su
bs
ta
nc
e 
us
er
s =
 1
0
 
(25
.6%
)
N
on
-s
ub
sta
nc
e 
us
er
s =
 3
1
 
(75
.6%
)
Su
bs
ta
nc
e 
us
e 
do
es
 n
ot
 
pr
ed
ic
t c
on
ve
rs
io
n 
to
 
ps
yc
ho
sis
 in
 y
ou
ng
 
pe
op
le
 a
t U
H
R 
fo
r
 
ps
yc
ho
sis
A
PS
, a
tte
nu
at
ed
 p
os
iti
ve
 sy
m
pt
om
s; 
CH
R,
 c
lin
ic
al
 h
ig
h 
ris
k;
 C
ID
I, 
Co
m
po
sit
e 
In
te
rn
at
io
na
l D
ia
gn
os
tic
 In
te
rv
ie
w
; D
IG
S,
 D
ia
gn
os
tic
 In
te
rv
ie
w
 fo
r G
en
et
ic
 S
tu
di
es
; D
SM
-IV
, D
ia
gn
os
tic
 a
nd
 S
ta
tis
tic
al
 
M
an
ua
l o
f M
en
ta
l D
iso
rd
er
s; 
IC
D
-9
, I
nt
er
na
tio
na
l C
la
ss
ifi
ca
tio
n 
of
 D
ise
as
es
, N
in
th
 R
ev
isi
on
; K
SA
D
S-
E,
 K
id
di
e S
ch
ed
ul
e f
or
 A
ffe
ct
iv
e D
iso
rd
er
s a
nd
 S
ch
iz
op
hr
en
ia
 =
 E
pi
de
m
io
lo
gi
c V
er
sio
n;
 K
-S
A
D
S-
PL
, K
id
di
e 
Sc
he
du
le
 fo
r A
ffe
ct
iv
e 
D
iso
rd
er
s a
nd
 S
ch
iz
op
hr
en
ia
 =
 P
re
se
nt
 a
nd
 L
ife
tim
e;
 S
CA
N
, S
ch
ed
ul
e 
fo
r C
lin
ic
al
 A
ss
es
sm
en
t i
n 
N
eu
ro
ps
yc
hi
at
ry
; S
CI
D
, S
ch
ed
ul
e 
fo
r C
lin
ic
al
 In
te
rv
ie
w
 a
nd
 D
ia
gn
os
is;
 
U
H
R,
 u
ltr
a-
hi
gh
 ri
sk
.
† A
ll 
of
 th
es
e 
pa
rti
ci
pa
nt
s w
er
e 
pa
rt 
of
 th
e 
Ca
nn
on
 e
t a
l.3
3  
st
ud
y.
 H
ow
ev
er
, m
or
e 
de
ta
ils
 w
er
e 
av
ai
la
bl
e 
fo
r e
ac
h 
pa
rti
ci
pa
nt
 in
 th
is 
stu
dy
.
‡ A
ll 
of
 th
es
e 
pa
rti
ci
pa
nt
s w
er
e 
pa
rt 
of
 th
e 
Ru
hr
m
an
n 
et
 a
l.3
4  
st
ud
y.
 H
ow
ev
er
, t
hi
s s
tu
dy
 fo
cu
se
d 
on
ly
 o
n 
ca
nn
ab
is 
us
e.
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